By Jess Jones Pharmaceuticals giant Astrazeneca has said it wants to hit $80bn (£62.9bn) in total revenue by 2030 through launching new medicines and investing in technology. The largest London-listed firm by market cap, which reported revenue of $45.8bn (£36bn) in 2023, aims to achieve this goal through growing its existing portfolio of oncology, biopharmaceuticals and rare disease drugs and launching an expected 20 new medicines. Pascal Soriot, chief executive at Astrazeneca said the firm today “announces a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a …
